Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
US12122850B2 · kind B2 · utility
0Cited by
58References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2023 |
| Grant date | Oct 22, 2024 |
| Priority date | — |
| Expiry date | Mar 14, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/71
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to GPC3×CD3 bispecific antibodies, GPC3×CD28 bispecific antibodies and the combination of two, agonistic and fully human KA-bodies with one targeting GPC3×CD3 and the other targeting GPC3×CD28, and both not competing for the binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3 positive malignancies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.